Drug Trial Radar · NCT06111274
A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Apr 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
82
Planned (sponsor's estimate)
Start
Oct 17, 2023
Primary completion
Dec 30, 2025
Study completion Dec 29, 2026
Sponsor
- Lead sponsor
- Abbisko Therapeutics Co, LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer. The main questions it aims to answer are: * Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is safe in patients with advanced pancreatic cancer. * Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is effective in patients with advanced pancreatic cancer. Participants will be asked to complete the study procedures: * Receive the administration of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab about 24 weeks in study Part A or Part B. * Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2. * Complete the study procedures specified in the protocol, which is guided by researchers.
Conditions
- Advanced Pancreatic Cancer
Interventions
Pimicotinib (ABSK021)Drug
The ABSK021 will be taken orally, once daily; The Gemcitabine and nab-Pacilitaxel will be administrated with intravenous infusion on day 1 and 8 of each cycle; The Toripalimab will be administrated with intravenous infusion on day 1 of each cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Event OccuranceTime frame: From the day signed informed consent form to day 90 after the end of cycle 8 (each cycle is 21 days)
- Objective Response Rate (ORR)Time frame: From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
West China Hospital of Sichuan University
Chengdu, China · Recruiting
Harbin Medical University Cancer Hospital
Ha’erbin, China · Recruiting
Shanghai East Hospital Tongji University
Shanghai, China · Recruiting
Union Hospital Tongji Medical College Huazhong University of science and technolog
Wuhan, China · Recruiting
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.